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Calcium-based phosphate binders are used to control
hyperphosphatemia; however, they promote hypercalcemia
and may accelerate aortic calcification. Here we compared
the effect of a phosphate binder containing calcium acetate
and magnesium carbonate (CaMg) to that of sevelamer
carbonate on the development of medial calcification in rats
with chronic renal failure induced by an adenine diet for
4 weeks. After 1 week, rats with chronic renal failure were
treated with vehicle, 375 or 750mg/kg CaMg, or 750mg/kg
sevelamer by daily gavage for 5 weeks. Renal function was
significantly impaired in all groups. Vehicle-treated rats with
chronic renal failure developed severe hyperphosphatemia,
but this was controlled in treated groups, particularly by
CaMg. Neither CaMg nor sevelamer increased serum calcium
ion levels. Induction of chronic renal failure significantly
increased serum PTH, dose-dependently prevented by CaMg
but not sevelamer. The aortic calcium content was
significantly reduced by CaMg but not by sevelamer. The
percent calcified area of the aorta was significantly lower
than vehicle-treated animals for all three groups. The
presence of aortic calcification was associated with increased
sox9, bmp-2, and matrix gla protein expression, but this did
not differ in the treatment groups. Calcium content in the
carotid artery was lower with sevelamer than with CaMg but
that in the femoral artery did not differ between groups.
Thus, treatment with either CaMg or sevelamer effectively
controlled serum phosphate levels in CRF rats and reduced
aortic calcification.
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Increased serum phosphate concentrations play a role in
transdifferentiation of vascular smooth muscle cells toward
osteochondrogenic cells that lead to mineralization of the
tunica media of large blood vessels in patients with chronic
kidney disease.1 This biological and bone-resembling process
is now well recognized as an important mechanism of medial
calcification in chronic renal failure (CRF), a pathological
process that ultimately leads to reduced elasticity of the blood
vessel wall,2 increased systolic blood pressure, and left
ventricle hypertrophy. Approximately 50% of the mortality
in hemodialysis patients is a direct consequence of
cardiovascular disease, of which medial calcification is a
major risk factor.3 Phosphate binders are administered to
control serum phosphorus levels in end-stage renal disease
patients, particularly when treated by dialysis. Phosphate
binders based on calcium are rather inexpensive and thus
frequently used. In addition, it was shown in an animal
model that they—probably because of their phosphate-
binding capacity—also slow the progression of vascular
calcification as compared with untreated CRF animals.4
However, compared with non-calcium-based phosphate
binders such as lanthanum carbonate (Fosrenol), sevelamer
carbonate (Renvela), and sevelamer hydrochloride (Renagel),
treatment with calcium-based agents may lead to an
increased number of hypercalcemic episodes, which may
promote development of vascular calcification.5 Hence, both
hyperphosphatemia6 and hypercalcemia7 may contribute to
vascular calcification. Another alternative phosphate-binding
agent is the calcium acetate/magnesium carbonate–
containing phosphate binder (OsvaRen, hereafter named
CaMg). The safety and efficacy of this and other magnesium-
based phosphate binders has already been demonstrated in
clinical studies,8–11 but their potential to prevent the
development and/or progression rate of vascular
calcification has not yet been investigated, although in vitro
studies have already shown a beneficial effect of magnesium
on the deposition of calcium and an inhibiting effect on the
osteogenic differentiation of cultured vascular smooth
muscle cells.12,13
In addition, data from clinical studies in dialysis patients
demonstrated that low serum magnesium concentrations are
associated with progression of vascular calcification14 and
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increased mortality.15 Higher serum magnesium levels have
been reported to protect against the development and
progression of vascular calcification,16 although the
mechanisms underlying this effect are rather unknown.
In this study, the effect of the magnesium-based phosphate
binder CaMg on the development of vascular calcification in
experimental CRF was investigated and compared with that of
sevelamer carbonate with equal amounts of active salt (for
details see ‘Materials and Methods’).
RESULTS
Rats were fed a 0.75% adenine/2.5% protein diet to induce
renal failure. After 1 week, treatment with phosphate binders
or vehicle was started until the time of killing at week 6
(Figure 1). There was limited mortality: one animal from
each treatment group died 1 day before the planned day of
killing. No statistically significant differences between groups
were seen for body weight and water and food consumption
(data not shown).
Biochemical analyses
Results of the biochemical analyses of serum and urine
samples are listed in Table 1 and Figure 2. A pronounced
renal failure was induced in all groups. Renal function
decreased significantly after 4 weeks of adenine/low protein
treatment as indicated by the increase in serum creatinine
concentrations, which were comparable between all groups
during the whole study period (Table 1). Hyperphosphatemia
developed in vehicle-treated rats and reached levels of up to
20mg/dl after 4 weeks of CRF (Table 1 and Figure 2a). At this
time point, treatment with 750mg/kg CaMg already
significantly reduced serum phosphorus levels, whereas this
reduction occurred only at week 6 for the sevelamer-treated
group. Urinary phosphate levels decreased in both CaMg-
treated groups from week 4 onwards, whereas sevelamer
lowered phosphate concentrations in the urine only at the
end of the study (Table 1 and Figure 2b). After 4 and 6 weeks
of CRF, serum intact fibroblast growth factor 23 (iFGF-23)
levels were dramatically increased in all groups; however,
phosphate binder treatment could not reduce iFGF-23
concentration in the circulation (Table 1). Total serum
calcium levels significantly increased in all phosphate
binder–treated groups compared with week 0 as well as in
CaMg-treated groups at the end of the study compared with
vehicle-treated animals (Table 1). However, ionized calcium
levels significantly decreased throughout the study in all
groups and no significant difference could be found between
groups at any time point (Table 1 and Figure 2c). Urinary
excretion of calcium was significantly increased in all groups
as compared with baseline values (Table 1). As could be
expected, serum magnesium concentrations dose-depen-
dently increased during the study in CRF groups treated
with CaMg (Table 1). Induction of CRF went along with a
significant increase in serum parathyroid hormone (PTH)
concentrations. Treatment with CaMg dose-dependently
suppressed this increase whereas sevelamer did not (Table 1).
Vascular calcification
After 6 weeks of CRF, vehicle-treated CRF animals developed
severe calcification in the aorta, femoral and carotid arteries
(aortic calcium content of rats with normal renal function
0.35±0.40mg per g wet tissue),17 as shown in Figure 3a
representing the aortic calcium content. Treatment with both
750mg/kg CaMg (CaMg750) and 375mg/kg CaMg
(CaMg375) significantly reduced the aortic calcium content
as compared with vehicle-treated CRF animals, whereas no
significant effect could be observed for sevelamer. Histolo-
gical analysis of von Kossa–stained sections of the aorta
showed a significantly reduced percent area of calcification in
the CaMg-treated animals as well as in the sevelamer-treated
group (Figure 3b). Treatment with sevelamer carbonate, but
not with CaMg, was associated with significant lower tissue
calcium content in the carotid artery. There was no
significant difference at all between CRF groups regarding
calcium content of the femoral artery.
Although no significant difference in the magnesium
content of the aorta could be found between groups,
magnesium content differed in the CaMg750 group for
carotid artery (increased) and in Sev750 for femoral artery
(decreased) compared with vehicle (Table 2). The Mg/Ca
ratio increased in all phosphate binder–treated groups, but
this should be interpreted in light of the reduced calcium
deposition in the vessels of these animals.
Synchrotron-based X-ray diffraction analysis of the aortic
calcifications in CaMg-, sevelamer- and vehicle-treated
animals indicated mineral precipitates of the various groups
to exclusively consist of calcium hydroxyapatite (Figure 4).
None of the samples contained whitlockite or any other type
of calcium phosphate mineral.
Gene expression analyses
Figure 5 illustrates the expression of osteochondrogenic genes
in the aorta. The expression of bmp-2 (bone morphogenetic
protein 2), the chondrocyte-specific transcription factor sox9
(sex determining region Y-box 9), and the calcification
inhibitor mgp (matrix gla protein) was significantly increased
in CRF rats compared with rats with normal renal function.
Interestingly, in CRF animals the expression of bmp-2, sox9,
and mgp was clearly associated with the presence of vascular
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Figure 1 | Study setup. CaMg, calcium acetate/magnesium
carbonate; CaMg375, CaMg 375 mg/kg; CaMg750, CaMg 750 mg/kg;
Sev750, 750 mg/kg sevelamer.
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calcification in the aorta. Despite a reduction of calcification,
there was no difference in the expression pattern of these
genes in the phosphate binder groups compared with vehicle
or between the different phosphate binder groups. There was
no change in the expression of osx (osterix), cbfa-1 (core
binding factor-a1), and the magnesium transporter TRPM7
Table 1 | Serum and urine biochemistry
Weeks of CRF
Baseline (n¼ 14
per group)
0 (n¼ 14
per group)
1 (n¼ 7
per group)
4 (n¼ 7
per group)
6 (n¼ 14
per group)
Serum creatinine (mg/dl)
Vehicle 0.28±0.02 0.32±0.05 0.66±0.161 4.21±1.051 2.11±0.601
CaMg750 0.27±0.041 0.34±0.05 0.61±0.111 4.10±0.981 3.08±1.14*1
CaMg375 0.28±0.04 0.31±0.02 0.71±0.341 4.11±0.781 2.23±0.551
Sev750 0.29±0.03 0.32±0.07 0.96±0.411 4.11±1.071 2.40±1.131
Serum P (mg/dl)
Vehicle 7.01±0.781 6.21±0.56 4.82±0.991 20.34±12.011 8.91±2.191
CaMg750 6.45±0.81 5.86±0.86 5.44±1.54 9.88±2.03*1 10.30±7.431
CaMg375 6.73±0.83 6.52±0.77 5.37±1.94 11.52±1.911 7.30±2.28
Sev750 6.75±0.78 6.47±1.12 6.06±1.75 16.26±9.201 8.06±7.09*
Serum Ca (mg/dl)
Vehicle 10.49±0.23 10.41±0.42 9.23±0.171 9.68±0.581 10.05±1.13
CaMg750 10.19±0.21* 10.44±0.65 9.33±0.161 10.65±0.47* 11.51±1.25*1
CaMg375 10.49±0.25 10.36±0.48 9.22±0.251 10.49±0.42 11.15±0.64*1
Sev750 10.68±0.18*1 10.25±0.46 9.37±0.221 10.12±0.74 10.99±0.551
Serum Mg (mg/dl)
Vehicle 1.95±0.081 1.74±0.05 1.70±0.09 2.80±0.281 2.42±0.251
CaMg750 2.00±0.131 1.77±0.14 1.90±0.24 6.82±0.77*1 5.44±1.68*1
CaMg375 1.90±0.141 1.72±0.09 1.84±0.17 4.99±0.55*1 3.37±0.51*1
Sev750 1.85±0.12* 1.79±0.15 1.97±0.15*1 2.74±0.231 2.78±0.441
Serum Ca2þ (mg/dl)
Vehicle 5.26±0.13 5.20±0.20 4.94±0.081 4.39±0.341 4.23±0.591
CaMg750 5.32±0.10 5.20±0.13 5.04±0.16 4.17±0.151 4.46±0.341
CaMg375 5.29±0.16 5.19±0.11 4.90±0.131 4.38±0.161 4.68±0.251
Sev750 5.32±0.09 5.24±0.10 4.96±0.201 4.44±0.361 4.55±0.401
Serum PTH (pg/ml)
Vehicle 213.0±1876 814.9±361.41 1109.3±270.91
CaMg750 209.7±148.9 46.3±18.8*1 325.2±293.2*
CaMg375 164.4±48.5 328.3±169.7 605.6±499.31
Sev750 198.1±67.0 677.4±136.81 963.6±648.11
Serum iFGF-23 (ng/ml)
Vehicle 0.30±0.05 0.38±0.10 166±1921 110±1281
CaMg750 0.32±0.09 0.47±0.22 47.4±52.61 277±148*1
CaMg375 0.26±0.09 0.71±0.58 87.7±65.41 217±2191
Sev750 0.30±0.09 0.87±0.66 75.3±61.61 99±1571
Serum pH
Vehicle 7.39±0.04 7.41±0.05 7.48±0.061 7.46±0.09 7.52±0.071
CaMg750 7.39±0.06 7.41±0.04 7.46±0.05 7.57±0.05*1 7.60±0.05*1
CaMg375 7.42±0.03 7.44±0.05 7.52±0.041 7.53±0.061 7.60±0.05*1
Sev750 7.40±0.05 7.42±0.04 7.49±0.08 7.48±0.051 7.56±0.061
Serum HCO3
 (mg/dl)
Vehicle 25.6±1.0 26.4±2.0 27.4±2.2 25.0±4.3 30.0±2.91
CaMg750 25.1±0.9 25.2±2.1 27.0±2.9 33.8±2.7*1 37.0±5.0*1
CaMg375 26.4±1.7 26.9±1.8 28.4±1.9 29.5±4.5 35.0±2.6*1
Sev750 25.3±1.6 26.1±1.4 26.6±2.5 26.1±0.6 32.1±3.41
Urine P (g/g creatinine)
Vehicle 8.45±2.68 7.12±1.18 0.94±0.901 5.17±1.371 10.73±2.361
CaMg750 7.66±1.61 7.91±1.72 1.05±0.621 1.85±0.89*1 5.27±7.05*1
CaMg 375 7.04±1.67 7.35±1.84 1.33±0.781 2.77±1.08*1 6.46±2.82*
Sev750 7.14±2.07 8.06±1.89 1.74±1.631 3.90±1.541 6.25±1.89*
Urine Ca (mg/g creatinine)
Vehicle 1.45±0.381 0.97±0.31 0.90±0.06 10.21±3.461 25.65±10.881
CaMg750 1.62±0.74 1.38±0.93 0.98±0.28 10.61±3.491 13.29±7.05*1
CaMg375 1.65±0.88 1.32±0.55 0.90±0.40 11.74±7.411 27.08±20.411
Sev750 1.59±0.90 1.03±0.361 0.87±0.33 11.39±3.811 25.58±19.711
Abbreviations: CaMg, calcium acetate/magnesium carbonate; CaMg375, CaMg 375 mg/kg; CaMg750, CaMg 750 mg/kg; CRF, chronic renal failure; iFGF-23, intact fibroblast
growth factor 23; PTH, parathyroid hormone; Sev, sevelamer; Sev750, sevelamer carbonate 750 mg/kg.
*Significant difference versus vehicle at the same time point.
1Significant difference versus week 0 of the same group.
Biochemical parameters are measured in serum and urine.
Data are expressed as mean±s.d.
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(transient receptor potential cation channel, subfamily M,
member 7) between CRF and normal renal function groups,
and there was no difference in the expression of these genes
between calcified and noncalcified vessels.
DISCUSSION
Based on clinical findings in dialysis patients, it has been
demonstrated that patients with reduced serum magnesium
concentrations have more arterial calcifications compared
with patients with normal or increased serum magnesium
values.14,16 In addition, low serum magnesium concen-
trations are associated with increased vascular stiffness18
and increased mortality15,19 (Passlick-Deetjen et al.,20 abstr-
act OM026 presented at ERA-EDTA 2010; Lacson et al.,21
abstract F-PO1488 presented at ASN 2009) whereas increased
serum magnesium improves intima media thickness22,23 and
pulse wave velocity in chronic kidney disease patients.23
Based on these observations, it was suggested that the use of a
phosphate binder in which part of the calcium is replaced by
magnesium might reduce vascular calcification by,
on one hand, reducing phosphate and calcium load and,
on the other hand, favoring the beneficial inhibitory effect of
magnesium.
However, until today, the effect of CaMg on development
and/or progression of vascular calcification has not been
investigated. In this experimental study using a rat model
with adenine-induced CRF, the effect of CaMg on the
development of vascular calcification was investigated and
compared with sevelamer carbonate, which has already been
proven to exert a beneficial effect on vascular calcification in
both experimental24 and clinical studies.5
Results show that hyperphosphatemia was effectively
controlled by treatment with 375 and 750mg/kg of CaMg
in adenine-induced CRF rats, doses that are significantly
lower than those previously reported in similar experimental
studies using other phosphate binders.25–27 According to the
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relative phosphate-binding coefficient of each phosphate
binder (based on our own unpublished data and those
reported in the studies of de Francisco et al.11 and Daugirdas
et al.28), a dose of 375mg/kg/day CaMg approximately
corresponds to a dose of 750mg/kg/day of sevelamer.
Despite the phosphate-lowering capacity of CaMg and
sevelamer, no reduction of serum iFGF-23 levels was
observed, which can probably be explained by the severity
of the renal impairment inherent to the adenine model and
the concomitant dramatically increased iFGF-23 levels going
along herewith. Another explanation could be that the
therapeutic period in this animal study was too short to have
an effect on iFGF-23.
There is increasing evidence (in vitro and in vivo) for
elevated phosphate to play a causal role in the induction of
vascular calcification in the aorta in synergy with calcium,29
as it may trigger the transdifferentiation of vascular smooth
muscle cells into osteochondrocyte-like cells. The efficient
control of serum phosphate by treatment with CaMg resulted
in significant reductions of aorta calcifications as measured
by the total tissue calcium content and by histology, even at
the lowest dose of CaMg. Significantly reduced aortic
calcifications in the aorta after treatment with sevelamer
were only seen after histological analysis of von Kossa–stained
sections of the aorta. Treatment with sevelamer resulted in
significantly less calcification in the carotid artery, whereas
this was not the case for CaMg. This may imply that the
mechanism inducing calcification in the aorta to a certain
extent differs from that in the smaller arteries that slightly
differ in constitution with respect to, for example, the amount
of elastin, collagen, or smooth muscle cells. The calcification
process in the peripheral arteries may be triggered by other
factors than those defined in more proximal arteries and possibly
depends to a lesser extent on circulating serum phosphate con-
centrations. In this context, it is worth mentioning that
sevelamer, apart from its phosphate-lowering capacity, also
reduces low-density lipoprotein concentrations and exerts
anti-inflammatory effects,30,31 aspects that may play a causal
role in the calcification process of arteries as well. However, for
the femoral artery, we could not observe an effect of any of the
phosphate binders on calcification. Additional studies are
required to further present evidence for these observations.
Table 2 | Calcium and magnesium content in the aorta, carotid and femoral arteries
Aorta Carotid artery Femoral artery
Ca (mg/g) Mg (mg/g) Mg/Ca ratio Ca (mg/g) Mg (mg/g) Mg/Ca ratio Ca (mg/g) Mg (mg/g) Mg/Ca ratio
Vehicle (n¼ 14) 54.5±29.7 2.75±1.66 0.072±0.064 24.2±19.1 2.19±1.41 0.084±0.016 6.50±3.78 0.71±0.34 0.112±0.018
CaMg750 (n¼ 14) 24.9±16.5* 2.72±1.61 0.137±0.065* 21.3±18.5 3.33±2.22* 0.160±0.090* 6.98±3.84 1.19±0.55 0.194±0.091*
CaMg375 (n¼ 14) 17.8±13.2* 1.84±1.44 0.135±0.074* 14.9±16.4 1.98±2.02 0.188±0.134* 4.69±3.60 0.66±0.42 0.149±0.042*
Sev750 (n¼ 14) 33.4±34.2 1.98±1.81 0.128±0.103 8.0±12.1* 1.09±1.14 0.200±0.165* 2.79±4.70 0.52±0.50* 0.165±0.079*
Abbreviations: CaMg, calcium acetate/magnesium carbonate; CaMg375, CaMg 375 mg/kg; CaMg750, CaMg 750 mg/kg; Sev, sevelamer; Sev750, sevelamer carbonate 750 mg/kg.
*Significant difference versus vehicle.
Data are expressed as mean±s.d.
Tissue calcium, magnesium concentration, and Mg/Ca ratio in the different blood vessels.
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Figure 4 | Calcium X-ray fluorescence and X-ray diffraction patterns of the deposited mineral in the calcified aorta of a uremic rat
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In addition to its phosphate-lowering capacity, magnesium
may also directly influence the development of medial calci-
fication by other mechanisms32 (Montes de Oca Gonzales
et al.,33 abstract FR-PO1195 presented at ASN 2011). It is
already known that at low concentrations, magnesium ions
can interact with the initiation and growth of calcium
phosphate crystals.32 In this study, microsynchrotron-based
X-ray diffraction analysis revealed that the mineral deposited
in the calcified regions had the physicochemical charac-
teristics of hydroxyapatite and that there was no evidence for
the presence of whitlockite, neither was there any particular
difference in the precipitation phase between CaMg,
sevelamer, and the non-treated CRF groups. With regard
to the absence of whitlockite in this study, it should be
mentioned that the Mg/Ca ratios in the aorta of CaMg-
treated animals, even though being slightly elevated com-
pared with vehicle, were distinctly lower than the values
reported in the study of Verberckmoes et al.34 using CRF rats
with calcitriol-induced vascular calcification.
The inhibitory effect of CaMg and sevelamer on the
development of aortic calcification was not reflected by a
decreased expression of osteochondrogenic markers. It is
remarkable that the expression of sox9, bmp-2, and mgp,
which are upregulated in uremic rats, is associated with the
presence or absence (‘on/off ’ situation) of aortic calcification.
The most probable explanation for the relatively high
expression of the osteochondrogenic proteins in the phos-
phate binder groups is that osteochondrogenic conversion of
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Osx, osterix; Sev, sevelamer; Sev750, sevelamer carbonate 750 mg/kg; sox9, sex determining region Y-box 9; TRPM7, transient receptor
potential cation channel, subfamily M, member 7; VC, vascular calcification; VK, von Kossa positivity. *Significant difference versus NRF;
1significant difference versus VC of the same group.
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vascular cells precedes the calcification process.35,36 As most
of the animals of the CaMg and sevelamer groups still present
calcification in the aorta—although it might merely be a mild
degree of calcification—one may reasonably accept that the
expression of the osteochondrogenic markers was not
inhibited. The mRNA expression of the magnesium trans-
porter TRPM7 in the aorta had not changed despite increased
serum magnesium levels in the CaMg groups. This is in
accordance with recent in vitro studies investigating the
effects of magnesium on the osteogenic transdifferentiation
process of vascular smooth muscle cells.13 An inhibitory
effect of magnesium on calcium deposition was observed in
vascular smooth muscle cells cultured in high phosphate
medium to induce calcification.13 Despite no regulation on
transcriptional levels of TRPM7, addition of magnesium to
the calcification medium restored or even increased the
activity of TRPM7 and prevented calcification, indicating a
possible role of this transporter and of magnesium in the
transdifferentiation process of vascular smooth muscle cells.
Indeed, addition of magnesium inhibited the upregulation of
calcification-associated genes like sox9 and msx2 induced by
high phosphate in vascular smooth muscle cells.12
Treatment with phosphate binders did not result in
increased ionized calcium levels in the serum, not even in
CRF rats treated with CaMg, which is in line with data from
patients treated with this phosphate binder.11 This is an
important finding as free serum calcium rather than protein-
bound calcium triggers the development of vascular
calcifications.28,37 It is worth mentioning that the absence
of any increase in serum ionized calcium levels in the CaMg
groups versus the vehicle or sevelamer groups was seen
despite a tendency toward higher total serum calcium levels.
Most probably, this may be explained by the somewhat
higher serum pH and bicarbonate (HCO3
 ) levels favoring
the protein binding of calcium (and of magnesium) in the
CaMg groups.38
Treatment of CRF rats with CaMg750 and CaMg375 dose-
dependently inhibited the increase of serum PTH seen in
untreated CRF animals. Yet, serum ionized calcium levels
were similar in vehicle- and CaMg-treated CRF rats. This
suggests other factor(s) to be responsible for the inhibition of
PTH secretion. Here, the lower serum phosphorus levels seen
in both CaMg groups as compared with vehicle- and
sevelamer-treated groups may at least in part explain the
lower serum PTH concentrations. In addition to this,
treatment with both CaMg doses resulted in a significant
increase in serum magnesium values as compared with
baseline. Magnesium is well known to act as a calcimimetic
and thus may also directly inhibit PTH secretion.39
Conclusion
The results of this study indicate that treatment with the Mg-
containing phosphate binder CaMg at a dose of 750mg/kg as
well as 375mg/kg was effective in preventing hyperpho-
sphatemia and did not induce rises in serum ionized calcium
levels. Moreover, CaMg at a dose of 750mg/kg prevented
serum PTH increases inherent to renal failure. Both doses of
CaMg as well as 750mg/kg sevelamer were overall compar-
ably effective in preventing the development of aortic
calcification, quantified by calcium content. Therefore,
phosphate binders in which part of the calcium is replaced
by magnesium might be a good alternative for calcium
acetate/carbonate in dialysis patients with vascular calcifica-
tion. The beneficial effect of treatment with CaMg on
vascular calcification found in this study is promising but
requires confirmation in further clinical studies.
MATERIALS AND METHODS
Animal procedures
All animal procedures were approved by the ethical committee of
the University of Antwerp. Fifty-six male Wistar rats (ca. 250 g,
Charles River, Lille, France) were randomly assigned to four groups:
(1) Vehicle (control group), (2) CaMg 750mg/kg (CaMg750), (3)
CaMg 375mg/kg (CaMg375), and (4) sevelamer carbonate 750mg/
kg (Sev750) (Figure 1). CRF was induced in all groups by feeding a
0.75% adenine/2.5% protein diet for 4 weeks. Before CRF induction,
rats were preconditioned on a 1.03% phosphorus diet for 2 weeks.
This diet was also given to the animals from week 4 until the time of
killing at week 6. All diets were provided by SSNIFF Spezialdia¨ten
(Soest, Germany).
One tablet of the magnesium-based phosphate binder CaMg
contains 435mg calcium acetate, equivalent to 110mg elemental
calcium, and 235mg heavy magnesium carbonate, equivalent to
60mg elemental magnesium. The dosage treatments represent the
amount of active salt either as MgCO3 and CaAc in the CaMg ratio
or as sevelamer carbonate. At 1 week after initiating the adenine
low-protein diet, treatment with phosphate binders was started by
daily oral gavage (7 days/week) until the day of killing (Figure 1). A
constant dose volume of 10ml/kg was respected. Hereto, CaMg was
dissolved in 1% carboxymethylcellulose. In order to obtain a
manageable gavaging solution, sevelamer was dissolved in water
instead of 1% carboxymethylcellulose. Control animals (vehicle)
were gavaged with 1% carboxymethylcellulose in the absence of
phosphate-binding agents.
Animals were housed in metabolic cages during the study period
for collection of urine samples (Figure 1). The housing was
restricted to 4 h and was followed by blood sampling. Hereto,
animals of each group were divided into two subgroups in which
urine and blood sampling were performed alternately.
After 6 weeks of CRF, animals were killed by exsanguination
through the retro-orbital plexus after anesthesia with intraperitoneal
injection of 60mg/kg pentobarbital (Nembutal, Ceva Sante´
Animale, Libourne, France).
Biochemistry
Serum calcium, phosphorus, and creatinine were measured on a
Vitros 5.1 Fusion auto-analyzer system (Ortho Clinical Diagnostics,
Rochester, NY). Serum ionized calcium, pH, and bicarbonate
(HCO3
 ) were measured with iSTAT (Abott Diagnostics, Wavre,
Belgium). Serum magnesium and urinary calcium were measured
with flame atomic absorption spectrometry (Perkin-Elmer, Well-
esley, MA) after appropriate dilution in 0.1% La(NO3)3. Serum PTH
was determined at weeks 0, 4, and 6 with the rat PTH IRMA kit
(Immunotopics, San Clemente, CA). Measurement of intact
FGF-23 was done by ELISA (Kainos Laboratories, Tokyo, Japan).
Urinary phosphate was measured using the EcolineS Phosphate kit
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(DiaSys, Holzheim, Germany). Urinary parameters were expressed
as mg/g creatinine.
Evaluation of vascular calcification
After isolation of the thoracic aorta, tissue was fixed in neutral
buffered formalin and cut in B20 cross-sections of 2–3mm. These
sections were embedded upright in a paraffin block and a 4-mm
coupe was stained for vascular calcification with von Kossa’s method
and counterstained with hematoxylin and eosin. The percentage of
calcified area was calculated using Axiovision Release 4.5 image
analysis software (Carl Zeiss, Oberkochen, Germany) in which two
color separation thresholds measure the total tissue area and the von
Kossa–positive area. After summing both absolute areas, the
percentage of calcified area was then calculated as the ratio of the
von Kossa–positive area versus the total tissue area.
The proximal part of the abdominal aorta and the left femoral
and carotid arteries were isolated and weighted on a precision
balance. Subsequently, samples were digested in 65% HNO3 at 60 1C
overnight. The calcium and magnesium content of the tissue was
measured with flame atomic absorption spectrometry (Perkin-
Elmer) and expressed as mg calcium or magnesium per g wet tissue.
Unstained 10 mm-thick aorta sections were used for synchrotron
X-ray m-fluorescence and X-ray m-diffraction analysis on beamline
ID18 of the European Synchrotron Radiation Facility, applying the
experimental setup as previously reported by Verberckmoes et al.31
In brief, a 2-dim 135mm MAR charge-coupled device–based
diffraction camera was used to capture the diffraction patterns.
The m-focused monochromatic X-ray beam with energy of 14.4 keV
was used to scan either the synthetic control samples or the aorta
samples. By applying this energy, the experiment benefited from the
revolver undulator of beamline ID18 that was optimized at this
energy. X-ray fluorescence mapping for calcium allowed to identify
calcified regions within the aorta sections. Per sample, several line
scans of adequate length were recorded to obtain sufficient
information and to analyze the spatial heterogeneity of the mineral
phases. Synthetic hydroxyapatite (Ca5(OH)(PO4)3), whitlockite
(Ca9(Mg,Fe)(PO3)(OH)(PO4)6), and brushite (CaHPO4.2H2O),
prepared following standardized methods, were used as positive
controls. These standards were available as powder. The m-
diffraction patterns were analyzed with the X-ray diffraction
software package FIT2D,40 (European Synchrotron Radiation
Facility, Grenoble, France) and after background correction of the
integrated X-ray diffraction spectra, the diffraction spectra of
the samples were compared with the reference diffraction spectra
of the standards from the diffraction database PCPDFWIN version
2.1 (International Centre of Diffraction Data, Newtown Square, PA).
Gene expression analysis
Total mRNA was extracted from the distal abdominal aorta with the
RNeasy Fibrous Tissue mini kit (Qiagen, Hilden, Germany) and
transcribed to cDNA with the High capacity cDNA archive kit
(Applied Biosystems, Foster City, CA). The PCR to quantify mRNA
was based on the Taqman fluorescence method (ABI prism 7000
sequence detection system, Applied Biosystems). Taqman probes and
primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
Rn99999916_s1), cbfa-1 (Rn01512296_m1), sox9 (Rn01751069_mH),
mgp (Rn00563463_m1), bmp-2 (Rn01484736_m1), osx
(Rn02769744_s1), and TRPM7 (Rn00586779_m1) were purchased
from Applied Biosystems as a Taqman gene expression assay. Each
gene was analyzed in triplicate and the expression was normalized to
the housekeeping gene GAPDH. Calculations were made to conform
with the comparative CT method using aortas of rats with normal
renal function as calibrator samples (historical data with a low-
protein diet from previous studies performed in our lab), which was
given a gene of interest/GAPDH expression ratio of 1.
Statistics
Results are expressed as mean±s.d. unless otherwise indicated.
Nonparametric statistical analyses were performed with SPSS 18.0
software (Brussels, Belgium). Statistical differences were investigated
with Kruskall–Wallis test followed by Mann–Whitney U-test.
Bonferroni correction was applied when more than two groups
were compared. Po0.05 was considered significant.
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